Johnson & Johnson Expands U.S. Availability of TECNIS PureSee Lens
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- Market Expansion: Johnson & Johnson has expanded the U.S. availability of its TECNIS PureSee intraocular lens, aiming to help more surgeons and patients access this lens, which has already been implanted in over 500,000 eyes worldwide, with a 97% patient recommendation rate indicating strong market acceptance.
- Surgical Safety: With cataract surgery success rates nearing 98%, the choice of TECNIS PureSee lens is crucial for post-operative vision, especially considering that nearly 20% of Americans aged 40 and older are affected by cataracts, highlighting significant market demand.
- Technological Innovation: TECNIS PureSee is the first FDA-approved extended-depth-of-focus lens without a warning for loss of contrast sensitivity, maintaining comparable contrast sensitivity to aspheric monofocal lenses, thereby enhancing visual performance for patients in low-light or foggy conditions.
- Patient-Centric Approach: The lifestyle-based vision quiz introduced by Johnson & Johnson helps patients understand their visual priorities, reflecting the company's commitment to innovation in surgical vision while addressing the growing demand for vision solutions that align with patients' lifestyle needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 238.490
Low
190.00
Averages
218.50
High
240.00
Current: 238.490
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson's IMAAVY Study Shows Significant Hemoglobin Improvement
- Clinical Trial Results: The Phase 2/3 ENERGY study demonstrated that IMAAVY (nipocalimab-aahu) produced a statistically significant durable hemoglobin response in the 30 mg/kg treatment group, with patients showing an average hemoglobin increase of at least 1 g/dL as early as Week 1, indicating rapid efficacy.
- Comparison to Placebo: Approximately three times as many patients in the IMAAVY group achieved durable hemoglobin levels by 24 weeks compared to the placebo group, highlighting the drug's potential in treating warm autoimmune hemolytic anemia (wAIHA).
- Fatigue Improvement and Steroid Reduction: The study also noted positive effects in fatigue improvement and reduction in steroid use, with nearly two-thirds of patients reaching the targets of hemoglobin ≥10 g/dL and an increase of ≥2 g/dL by Week 24.
- Safety and Regulatory Progress: IMAAVY's safety profile was consistent with its established safety in approved indications, with no new safety signals reported, supporting its supplemental Biologics License Application (sBLA) to the FDA, which has been granted Priority Review.
See More
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee Lens
- Market Expansion: Johnson & Johnson has expanded the U.S. availability of its TECNIS PureSee intraocular lens, aiming to help more surgeons and patients access this lens, which has already been implanted in over 500,000 eyes worldwide, with a 97% patient recommendation rate indicating strong market acceptance.
- Surgical Safety: With cataract surgery success rates nearing 98%, the choice of TECNIS PureSee lens is crucial for post-operative vision, especially considering that nearly 20% of Americans aged 40 and older are affected by cataracts, highlighting significant market demand.
- Technological Innovation: TECNIS PureSee is the first FDA-approved extended-depth-of-focus lens without a warning for loss of contrast sensitivity, maintaining comparable contrast sensitivity to aspheric monofocal lenses, thereby enhancing visual performance for patients in low-light or foggy conditions.
- Patient-Centric Approach: The lifestyle-based vision quiz introduced by Johnson & Johnson helps patients understand their visual priorities, reflecting the company's commitment to innovation in surgical vision while addressing the growing demand for vision solutions that align with patients' lifestyle needs.
See More
Johnson & Johnson Seeks Imaavy Label Expansion for Rare Disease
- Clinical Trial Results: Johnson & Johnson's detailed Phase 2/3 ENERGY study results indicate that patients treated with Imaavy were approximately three times more likely to achieve durable hemoglobin levels compared to those on placebo, highlighting the drug's potential in treating warm autoimmune hemolytic anemia (wAIHA).
- FDA Priority Review: J&J has submitted a label expansion application for Imaavy to the FDA, which is currently under priority review; early data shows that Imaavy patients achieved a higher rate of durable hemoglobin response than placebo, enhancing its market outlook.
- Market Opportunity: With no FDA-approved therapies currently available for wAIHA, J&J has the potential to be the first mover in this rare disease market, opening new revenue streams and strengthening its competitive position in the biopharmaceutical sector.
- Safety Consistency: J&J noted that Imaavy's safety profile aligns with its known tolerability in myasthenia gravis patients, providing additional confidence for its application in the new indication and potentially accelerating market acceptance.
See More
Johnson & Johnson Expands TECNIS PureSee Lens Rollout in the U.S.
- Product Innovation: Johnson & Johnson's TECNIS PureSee intraocular lens is the first FDA-approved extended depth of focus lens without a warning on loss of contrast sensitivity, aimed at improving visual quality for cataract surgery patients, marking a significant technological advancement in ophthalmology.
- Patient Feedback: With 97% of patients reporting no very bothersome visual disturbances, this high satisfaction rate not only enhances patients' quality of life but also provides strong support for Johnson & Johnson's competitiveness in the ophthalmic market.
- Market Expansion: The full U.S. rollout of the TECNIS PureSee IOL reflects Johnson & Johnson's commitment to innovation and patient satisfaction, which is expected to further enhance its market share in the ophthalmic device sector.
- Strategic Implications: This expansion not only meets the market demand for high-quality visual solutions but may also drive long-term growth for Johnson & Johnson in the medical device field, solidifying its leadership position in the industry.
See More
Johnson & Johnson Reports Data for Imaavy Label Expansion
- Clinical Trial Results: Johnson & Johnson's Phase 2/3 ENERGY study data reveals that patients treated with Imaavy achieved durable hemoglobin levels at a rate approximately three times higher than those on placebo, indicating the drug's potential in treating warm autoimmune hemolytic anemia (wAIHA).
- FDA Review Progress: The marketing application for Imaavy's label expansion in wAIHA is currently under FDA priority review, with initial data showing that more patients met the primary endpoint, suggesting a promising outlook for the drug's application in this rare condition.
- Safety Analysis: The study involving 115 subjects demonstrated that Imaavy's safety profile is consistent with its known tolerability in myasthenia gravis, further bolstering confidence in its use for the new indication.
- Market Opportunity: Given that there are currently no FDA-approved therapies for wAIHA, the potential label expansion for Imaavy presents Johnson & Johnson with new market opportunities to address unmet medical needs.
See More
Johnson & Johnson's IMAAVY Shows Promise for Autoimmune Anemia
- Clinical Trial Results: Johnson & Johnson's IMAAVY demonstrated a significant breakthrough in the Phase 2/3 ENERGY study, where patients receiving a 30 mg/kg dose achieved an average hemoglobin increase of at least 1 g/dL as early as Week 1, addressing a rare autoimmune disease with no FDA-approved treatments.
- Significant Efficacy: Patients treated with IMAAVY experienced approximately three times as many durable hemoglobin responses compared to the placebo group by Week 24, indicating the therapy's potential to enhance patient quality of life significantly.
- Reduced Side Effects: Patient-reported outcomes showed that IMAAVY not only improved fatigue but also reduced corticosteroid use, suggesting that the therapy effectively addresses symptoms of autoimmune hemolytic anemia while preserving immune function.
- Urgent Market Need: With no FDA-approved therapies available, wAIHA patients rely on steroids and immunosuppressants; the success of IMAAVY could provide a new solution for this high unmet medical need.
See More
Johnson & Johnson's IMAAVY Study Shows Significant Hemoglobin Improvement
- Clinical Trial Results: The Phase 2/3 ENERGY study demonstrated that IMAAVY (nipocalimab-aahu) produced a statistically significant durable hemoglobin response in the 30 mg/kg treatment group, with patients showing an average hemoglobin increase of at least 1 g/dL as early as Week 1, indicating rapid efficacy.
- Comparison to Placebo: Approximately three times as many patients in the IMAAVY group achieved durable hemoglobin levels by 24 weeks compared to the placebo group, highlighting the drug's potential in treating warm autoimmune hemolytic anemia (wAIHA).
- Fatigue Improvement and Steroid Reduction: The study also noted positive effects in fatigue improvement and reduction in steroid use, with nearly two-thirds of patients reaching the targets of hemoglobin ≥10 g/dL and an increase of ≥2 g/dL by Week 24.
- Safety and Regulatory Progress: IMAAVY's safety profile was consistent with its established safety in approved indications, with no new safety signals reported, supporting its supplemental Biologics License Application (sBLA) to the FDA, which has been granted Priority Review.
See More
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee Lens
- Market Expansion: Johnson & Johnson has expanded the U.S. availability of its TECNIS PureSee intraocular lens, aiming to help more surgeons and patients access this lens, which has already been implanted in over 500,000 eyes worldwide, with a 97% patient recommendation rate indicating strong market acceptance.
- Surgical Safety: With cataract surgery success rates nearing 98%, the choice of TECNIS PureSee lens is crucial for post-operative vision, especially considering that nearly 20% of Americans aged 40 and older are affected by cataracts, highlighting significant market demand.
- Technological Innovation: TECNIS PureSee is the first FDA-approved extended-depth-of-focus lens without a warning for loss of contrast sensitivity, maintaining comparable contrast sensitivity to aspheric monofocal lenses, thereby enhancing visual performance for patients in low-light or foggy conditions.
- Patient-Centric Approach: The lifestyle-based vision quiz introduced by Johnson & Johnson helps patients understand their visual priorities, reflecting the company's commitment to innovation in surgical vision while addressing the growing demand for vision solutions that align with patients' lifestyle needs.
See More
Johnson & Johnson Seeks Imaavy Label Expansion for Rare Disease
- Clinical Trial Results: Johnson & Johnson's detailed Phase 2/3 ENERGY study results indicate that patients treated with Imaavy were approximately three times more likely to achieve durable hemoglobin levels compared to those on placebo, highlighting the drug's potential in treating warm autoimmune hemolytic anemia (wAIHA).
- FDA Priority Review: J&J has submitted a label expansion application for Imaavy to the FDA, which is currently under priority review; early data shows that Imaavy patients achieved a higher rate of durable hemoglobin response than placebo, enhancing its market outlook.
- Market Opportunity: With no FDA-approved therapies currently available for wAIHA, J&J has the potential to be the first mover in this rare disease market, opening new revenue streams and strengthening its competitive position in the biopharmaceutical sector.
- Safety Consistency: J&J noted that Imaavy's safety profile aligns with its known tolerability in myasthenia gravis patients, providing additional confidence for its application in the new indication and potentially accelerating market acceptance.
See More
Johnson & Johnson Expands TECNIS PureSee Lens Rollout in the U.S.
- Product Innovation: Johnson & Johnson's TECNIS PureSee intraocular lens is the first FDA-approved extended depth of focus lens without a warning on loss of contrast sensitivity, aimed at improving visual quality for cataract surgery patients, marking a significant technological advancement in ophthalmology.
- Patient Feedback: With 97% of patients reporting no very bothersome visual disturbances, this high satisfaction rate not only enhances patients' quality of life but also provides strong support for Johnson & Johnson's competitiveness in the ophthalmic market.
- Market Expansion: The full U.S. rollout of the TECNIS PureSee IOL reflects Johnson & Johnson's commitment to innovation and patient satisfaction, which is expected to further enhance its market share in the ophthalmic device sector.
- Strategic Implications: This expansion not only meets the market demand for high-quality visual solutions but may also drive long-term growth for Johnson & Johnson in the medical device field, solidifying its leadership position in the industry.
See More
Johnson & Johnson Reports Data for Imaavy Label Expansion
- Clinical Trial Results: Johnson & Johnson's Phase 2/3 ENERGY study data reveals that patients treated with Imaavy achieved durable hemoglobin levels at a rate approximately three times higher than those on placebo, indicating the drug's potential in treating warm autoimmune hemolytic anemia (wAIHA).
- FDA Review Progress: The marketing application for Imaavy's label expansion in wAIHA is currently under FDA priority review, with initial data showing that more patients met the primary endpoint, suggesting a promising outlook for the drug's application in this rare condition.
- Safety Analysis: The study involving 115 subjects demonstrated that Imaavy's safety profile is consistent with its known tolerability in myasthenia gravis, further bolstering confidence in its use for the new indication.
- Market Opportunity: Given that there are currently no FDA-approved therapies for wAIHA, the potential label expansion for Imaavy presents Johnson & Johnson with new market opportunities to address unmet medical needs.
See More
Johnson & Johnson's IMAAVY Shows Promise for Autoimmune Anemia
- Clinical Trial Results: Johnson & Johnson's IMAAVY demonstrated a significant breakthrough in the Phase 2/3 ENERGY study, where patients receiving a 30 mg/kg dose achieved an average hemoglobin increase of at least 1 g/dL as early as Week 1, addressing a rare autoimmune disease with no FDA-approved treatments.
- Significant Efficacy: Patients treated with IMAAVY experienced approximately three times as many durable hemoglobin responses compared to the placebo group by Week 24, indicating the therapy's potential to enhance patient quality of life significantly.
- Reduced Side Effects: Patient-reported outcomes showed that IMAAVY not only improved fatigue but also reduced corticosteroid use, suggesting that the therapy effectively addresses symptoms of autoimmune hemolytic anemia while preserving immune function.
- Urgent Market Need: With no FDA-approved therapies available, wAIHA patients rely on steroids and immunosuppressants; the success of IMAAVY could provide a new solution for this high unmet medical need.
See More
